TJ Johnson, John Lubniewski
HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.
Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.
Deanna Church has joined gene editing technology company Inscripta as senior director of mammalian applications. Previously, she was senior director of applications at 10x Genomics, and before that, senior director of genomics and content at Personalis. Prior to that, she was a staff scientist at the National Center for Biotechnology Information. Church holds a PhD in genomics, genetics, and molecular biology from the University of California, Irvine, and a BA in liberal arts from the University of Virginia.
Jonathan Jaglom, Gil Ronen
NRGene said this week that it has appointed Jonathan Jaglom as the firm's CEO. Jaglom succeeds NRGene's cofounder Gil Ronen, who has transitioned to the firm's president. Jaglom previously served as NRGene's chief operating officer. Prior to joining NRGene in 2018, Jaglom served as CEO of MakerBot. He has also held executive roles at Stratasys, including general manager and VP of sales operations.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.